EUVIMEDEUVIMED entdecken
Open Access

Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort

George Nassief iD, Tolulope Adeyelu, Andrew Elliott, Jordan Phillipps, Renee Morecroft, Alice Y Zhou iD, Peter W Szlosarek iD, Caroline Robert iD, Farah Abdulla, Ari Vanderwalde iD, Soo J Park, David Chen iD und 1 weitere

JCO Precision Oncology · 2026-01 · 10 (1)

DOI: 10.1200/po-25-00923 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-01. Verfasst von George Nassief und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Washington University in Saint Louis, Saint Louis, MO. Hauptthemen laut MEDLINE: Skin Neoplasms, Melanoma, Homologous Recombination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Homologous recombination deficiency (HRD) results in DNA instability in tumor cells and contributes to tumor pathogenesis. Although HRD-directed therapies are established in other cancers, their role in skin cancers remains unclear. Given the poor response to standard therapies in skin cancer subtypes like acral and mucosal melanoma, we aimed to characterize the prevalence of HRD across skin cancer subtypes, evaluate its correlation with immune checkpoint inhibitor (ICI) response biomarkers, and assess its prognostic relevance in patients treated with immunotherapy (IO). METHODS A total of 2,508 patients with skin cancer underwent molecular profiling including whole-exome sequencing, whole-transcriptome sequencing, and immunohistochemistry. HRD status was defined by a high loss of heterozygosity (LOH-high) or mutations in homologous recombination repair (HRR) genes. Associations between HRD and established ICI biomarkers (tumor mutational burden, PD-L1, deficient mismatch repair/microsatellite instability-high, immune cell fractions, and transcriptomic signatures) were assessed. Survival outcomes on ICI therapy were assessed in cutaneous melanoma using insurance claims data. RESULTS Overall, among the melanoma subtypes, mucosal and acral melanoma had a greater prevalence of LOH-high than cutaneous (30.9% v 13.1% v 8.3%, P < .001). Generally, LOH-high in skin cancer did not correlate with mutations in HRR genes. Additionally, there was no significant association in ICI response biomarkers and HRD among patients with skin cancers. Furthermore, HRD was not associated with a prognostic advantage following IO (hazard ratio, 0.981 [CI, 0.80 to 1.20]; P = .854). CONCLUSION HRD defines a biologically distinct subset of skin cancers and is not predictive of ICI response or improved outcomes. The high prevalence of HRD in acral and mucosal melanoma highlights the need to investigate HRD-directed therapies strategies in this distinct cohort, such as poly (ADP-ribose) polymerase inhibitors or platinum-based therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsMelanomaHomologous RecombinationHumansMaleFemalePrevalenceAgedMiddle AgedLoss of HeterozygosityCohort StudiesPrognosisImmune Checkpoint Inhibitors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, Washington University in Saint Louis, Saint Louis, MO.
  • Caris Life Sciences, Phoenix, AZ.
  • Cancer Research UK Translational Oncology Laboratory, Barts and the London, London, United Kingdom.
  • Gustave Roussy Cancer Campus, Villejuif, France.
  • Division of Hematology/Oncology, Moores Cancer Center, University of California San Diego, La Jolla, CA.
  • Division of Dermatology, Department of Medicine, Washington University in Saint Louis, Saint Louis, MO.

ORCID-Profile: George Nassief, Alice Y Zhou, Peter W Szlosarek, Caroline Robert, Ari Vanderwalde, David Chen, George Ansstas

Zitieren

APA

Nassief, G., Adeyelu, T., Elliott, A., Phillipps, J., Morecroft, R., Zhou, A. Y., Szlosarek, P. W., Robert, C., Abdulla, F., Vanderwalde, A., Park, S. J., Chen, D., & Ansstas, G. (2026). Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort. JCO Precision Oncology, 10(1). https://doi.org/10.1200/po-25-00923

Vancouver

Nassief G, Adeyelu T, Elliott A, Phillipps J, Morecroft R, Zhou AY, et al. Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort. JCO Precision Oncology. 2026;10(1). doi:10.1200/po-25-00923

BibTeX
@article{Nassief2026,
  author = {Nassief, George and Adeyelu, Tolulope and Elliott, Andrew and Phillipps, Jordan and Morecroft, Renee and Zhou, Alice Y and Szlosarek, Peter W and Robert, Caroline and Abdulla, Farah and Vanderwalde, Ari and Park, Soo J and Chen, David and Ansstas, George},
  title = {Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {1},
  doi = {10.1200/po-25-00923}
}
Kostenlos starten →